CGN On Other Exchanges
New York
text size: T | T
Back to Snapshot
Company Description

Contact Info

900 Cottage Grove Road

Bloomfield, CT 06002

United States

Phone: 860-226-6000

Fax: 860-226-6741

e Market, and Select segments. In marketing these products, the company primarily sells through insurance brokers and consultants, and employed a direct sales force that consisted of approximately 265 sales professionals in 27 office locations as of December 31, 2015. Other Operations Other Operations includes the following businesses: Corporate-owned Life Insurance (COLI) The principal products of the COLI business are permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for the purpose of financing employer-paid future benefit obligations. Permanent life insurance provides coverage that, when adequately funded, does not expire after a term of years. The contracts are primarily non-participating universal life policies. Run-off Settlement Annuity Business The company’s settlement annuity business is a closed, run-off block of single premium annuity contracts. These contracts are primarily liability settlements with approximately 21% of the liabilities associated with payments that are guaranteed and not contingent on survivorship. For contracts that involve non-guaranteed payments, such payments are contingent on the survival of one or more parties involved in the settlement. Individual Life Insurance and Annuity and Retirement Benefits Businesses This business includes the sale of the individual life insurance and annuity business, and the sale of the retirement benefits business. Strategy The company’s strategy is to ‘Go Deep’, ‘Go Global’, and ‘Go Individual’ with a differentiated set of medical, dental, disability, life and accident insurance and related products and services offered by its subsidiaries. Regulation The expansion of the company’s operations into foreign countries increases its exposure to certain U.S. laws, such as the Foreign Corrupt Practices Act of 1977. The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act mandate changes affecting insured and self-insured health benefit plans that impact the company’s business model, including its relationship with current and future customers, producers and health care providers, products, services, processes and technology. Certain of the company’s subsidiaries are pharmacies that dispense prescription drugs to participants of benefit plans administered or insured by its HMO and insurance company subsidiaries. These pharmacy-subsidiaries are subject to state licensing requirements and regulation, as well as U.S. Drug Enforcement Agency registration requirements. The company’s operations in countries outside the United States are subject to local regulations in the locations in which its subsidiaries conduct business; in some cases, are subject to regulations in the locations of customers; and in all cases, are subject to the Foreign Corrupt Practices Act of 1977. The company’s domestic subsidiaries sell majority of their products and services to sponsors of employee benefit plans that are governed by the Employee Retirement Income Security Act of 1974, as amended. The company’s domestic subsidiaries are subject to requirements imposed by the Employee Retirement Income Security Act of 1974, as amended affecting claim payment and appeals procedures for individual health insurance and insured and self-insured group health plans and for the insured dental, disability, life and accident plans that the company administers. Several of the company’s subsidiaries engage in businesses that are subject to federal Medicare regulations, such as those offering individual and group Medicare Advantage (HMO) coverage; those offering Medicare Pharmacy (Part D) products that are subject to federal Medicare regulations; and billing of Medicare Part B claims on behalf of providers with whom the company has contractual management agreements. Several of the company’s subsidiaries are also subject to reporting requirements pursuant to Section 111 of the Medicare, Medicaid and SCHIP Extension Act of 2007. The company is also subject to regulation by the Office of Foreign Assets Control of the Department of the Treasury, which administer


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CGN.
View Industry Companies

Industry Analysis


Industry Average

Valuation CGN Industry Range
Price/Earnings 16.0x
Price/Sales 0.8x
Price/Book 2.4x
Price/Cash Flow 14.8x
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CIGNA CORP, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at